Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor.
A77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, was administered to asymptomatic HIV-1-infected patients in a phase I trial. The drug was given by continuous intravenous infusion at dosages of 0.035, 0.07, 0.14, and 0.28 mg/kg of body weight per h. The drug was give...
-д хадгалсан:
| -д хэвлэсэн: | Antimicrob Agents Chemother |
|---|---|
| Үндсэн зохиолчид: | , , , , , , , , , |
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
American Society for Microbiology (ASM)
1995
|
| Нөхцлүүд: | |
| Онлайн хандалт: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC162781/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/7492104/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.7.1559 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
